Search results for " bispecifics"

Article Buffer optimization for separation of bsAb in a capture step using MabSelect™ VL resin
Protein L resins bind to kappa light chain and are often used to purify antibody fragments such as dAbs and Fabs — but they can also be used to remove product-related impurities from bispecif…

Article Get Started: Purification of mAb Variants - eLearning
The success of monoclonal antibodies (mAbs) as therapeutics and the multi-domain structure of antibodies has made it possible to create antibody variants, such as bispecific antibodies (bsAbs)…

Article Chromatography innovations for the diversified antibody pipeline
Introducing MabSelect™ VH3 affinity resin for antibody variants At Cytiva, we connect with process developers and manufacturers to understand their needs and strive to make t…

Article eBook: Purification of Antibody Therapeutics - Approach for Diversified Pipeline
Antibody therapeutics are the largest class of biotherapeutics. Over the years, development beyond traditional monoclonal antibodies (mAbs) has increased. Today, we see multispecific and bispe…

Article Platform for Purification of VHH-type Antibody Fragments
Click here to read this poster >> Protein A affinity chromatography resins have been used to purify monoclonal antibodies (mAbs) by the bioprocess industry at all scales for a long time. Howev…

Article The Challenge of Disruptive Technologies in Bioprocessing
In addition, there is a need for new resin chemistries for polishing end product because the bioprocessing of complex therapeutic molecules such as ADCs, antibody fragments, and bispecifics are result…

Article Process Chromatography: Continuous Optimization
Improved resin chemistries and customized separation solutions are enabling more efficient separations. By Cynthia A. Challener Cell-culture and fermentation are high-…

Article A Risk-Based Genetic Characterization Strategy for Recombinant CHO Cell Lines Used for Clinical and Commercial Applications
The authors describe the ways in which manufacturers can mitigate the risks related to the integrity of recombinant transgenes expressed in CHO cells. By Luhong He, Christopher Frye Abstract …

Article A Bright Future for the Plasma Fractionation Industry
There is still a very bright future for the plasma fractionation industry. That was one of the conclusions reached when the 9th Plasma Product Biotechnology (PPB) meeting ended on the beautiful isla…

Article Downstream Process Developers: What are Your Antibody Processing Challenges?
Process developers, we want to hear from you! We're asking PD scientists to tell us about their biggest challenges developing downstream processes for mAbs and their variants.  Take this …

Previous PageNext Page